|
|
|
|
|
|
by ramraj07
673 days ago
|
|
|
It’s phase 2, not peer review published yet but results are out -https://www.morningstar.com/news/globe-newswire/1000985090/l... Sounds significant. Phase II is typically not enough to tell if a drug is good because most drugs aren’t that effective compared to current standard of care- you need the large numbers of phase iii to see the real difference. But looks like this drug shows a marked improvement in phase ii itself so it’s actually quite impressive. Last time I read such a story was for imatinib. Expecting good things from this. |
|
|